APLN and diabetic kidney disease: The inhibition of FABP4 in APLNR-deficient mice restored glucose utilization and normalized FA uptake, emphasizing the potential of targeting the endothelial apelin/FOXO1/FABP4 axis to improve metabolic health in DKD.